The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder (Q38569937)

4 September 2017

The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder (English)

1 reference

4 September 2017

4

Maj Vinberg

1 reference

4 September 2017

1

Roger S McIntyre

1 reference

4 September 2017

Holly X Xiao

2

1 reference

4 September 2017

Kahlood Syeda

3

1 reference

4 September 2017

Andre F Carvalho

5

1 reference

4 September 2017

Rodrigo B Mansur

6

1 reference

4 September 2017

Nadia Maruschak

7

1 reference

4 September 2017

Danielle S Cha

8

1 reference

4 September 2017

20 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

29

1 reference

4 September 2017

7

1 reference

4 September 2017

577-589

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-015-0263-x

4 September 2017

0 references

cites work

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Grand challenges in global mental health: integration in research, policy, and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Depression in the workplace: effects on short-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

A vision for drug discovery and development: novel targets and multilateral partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Hot and cold cognition in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Definition and characterization of an extended social-affective default network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Higher-order social cognition in first-episode major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Effect of acute antidepressant administration on negative affective bias in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Low-dose tryptophan depletion in recovered depressed women induces impairments in autobiographical memory specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

The initial field trials of DSM-5: new blooms and old thorns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

How should remission from depression be defined? The depressed patient's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Using multiple methods to characterize the phenotype of individuals with a family history of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Never-depressed females with a family history of depression demonstrate affective bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive function in unaffected twins discordant for affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Translating scientific opportunity into public health impact: a strategic plan for research on mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

The role of cognitive impairment in general functioning in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Linking molecules to mood: new insight into the biology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Functional connectivity in the resting brain: a network analysis of the default mode hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Functional connectivity of default mode network components: correlation, anticorrelation, and causality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Psychometric properties of a performance-based measurement of functional capacity, the UCSD Performance-based Skills Assessment - Brief version

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Modafinil: a review of neurochemical actions and effects on cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognition enhancement by modafinil: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive functioning in psychiatric disorders following deep brain stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Physical activity and the prevention of depression: a systematic review of prospective studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cardiac peroxisome proliferator-activated receptor-γ expression is modulated by oxidative stress in acutely infrasound-exposed cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Effects of exercise on physical self-concept, global self-esteem, and depression in women of low socioeconomic status with elevated depressive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Successful computer-assisted cognitive remediation therapy in patients with unipolar depression: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0263-X

Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study.

21 January 2018

1 reference

12 December 2020

Psychostimulants for depression

1 reference

12 December 2020

Antidepressant use in persons aged 12 and over: United States, 2005-2008

1 reference

12 December 2020

The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials.

1 reference

12 December 2020

Using a self-report depression scale to identify remission in depressed outpatients

1 reference

12 December 2020

Cognition as a target in major depression: new developments

1 reference

12 December 2020

Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression

1 reference

12 December 2020

What stock market returns to expect for the future?

1 reference

12 December 2020

Exercise for depression

1 reference

12 December 2020

The economic burden of depression in the United States: how did it change between 1990 and 2000?

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

1 reference

12 December 2020

Neurocognitive deficits and disability in major depressive disorder

1 reference

12 December 2020

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Do Canada and the United States differ in prevalence of depression and utilization of services?

1 reference

12 December 2020

Perceived cognitive decline in multiple sclerosis impacts quality of life independently of depression

1 reference

12 December 2020

A distinct pattern of memory and attention deficiency in patients with depression.

1 reference

12 December 2020

Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction

1 reference

12 December 2020

10.1007/S40263-015-0263-X

Identifiers

DOI

1 reference

4 September 2017

1 reference